Search
Etrolizumab
go.drugbank.com/drugs/DB12189InvestigationalInflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as
Zibrofusidic acid
go.drugbank.com/drugs/DB20799InvestigationalZibrofusidic acid has a monoisotopic molecular weight of 594.26 Da. … Zibrofusidic acid is a small molecule drug.
BB 21217
go.drugbank.com/drugs/DB17373InvestigationalBB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP
RGX-501
go.drugbank.com/drugs/DB17639InvestigationalRGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.
Dabocemagene autoficel
go.drugbank.com/drugs/DB17878InvestigationalDabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.
Synonyms: THE CONTROL OF A HUMAN CYTOMEGALOVIRUS (CMV) PROMO, AUTOLOGOUS HUMAN DERMAL FIBROBLAST CELLS DERIVED FROM SKIN BIOPSIES, AND TRANSDUCED WITH A NON-REPLICATING, SELF-INACTIVATING LENTIVIRUS VECTOR THAT ENCODES HUMAN COLLAGEN TYPE VII ALPHA 1 (COL7A1) UNDERViralym-C
go.drugbank.com/drugs/DB17975InvestigationalViralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.
BO-653
go.drugbank.com/drugs/DB19216InvestigationalBO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.
Evixapodlin
go.drugbank.com/drugs/DB21520InvestigationalEvixapodlin has a monoisotopic molecular weight of 690.22 Da. … Evixapodlin is a small molecule drug.